TREATMENT OF RECURRENT TEMPOROMANDIBULAR JOINT DISLOCATION WITH BOTULINUM TOXIN | ||
| Alexandria Dental Journal | ||
| Article 10, Volume 40, Issue 2, December 2015, Pages 200-207 PDF (1.53 M) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/adjalexu.2015.59152 | ||
| Authors | ||
| B Shehata* ; S Darwish* ; T Aly* ; G Younis* | ||
| Master student at the Oral and Maxillofacial Surgery department, Faculty of Dentistry, Alexandria University. | ||
| Abstract | ||
| Introduction: The use of botulinum toxin type A (BTX-A) injection as it is a more recently reported treatment to alter the musculature with the intended effect to weaken the lateral pterygoid muscle (LPM) sufficiently to prevent temporomandibular joint (TMJ) dislocation. This caused a new imbalance between the muscles used for opening and closing the jaws, and mouth opening was slightly limited because of the weakness of the LPM. Objectives: To evaluate the efficacy of injection of BTX-A as the first choice of treatment for patients with chronic TMJ dislocation not responding to conservative line of treatment. Materials and methods: A prospective study was conducted on a total of 20 patients complaining of recurrent episodes of chronic TMJ dislocation. Group A: (The study group) patients were injected with BTX-A in the LPM through an intraoral approach, Group B: (The control group) patients suffering from chronic TMJ dislocation and treated by inter maxillary fixation (IMF). Results: The study revealed that injecting BTX-A in the LPM prevents the TMJ dislocation and reduced pain caused by the movement of the LPM by 90 % through temporary paralysis of the muscle, thus allowing the muscle to move more naturally. Conclusions: This is a relatively conservative option, injection into the muscle is straightforward and can be done in outpatients with few complications. | ||
| Keywords | ||
| Temporomandibular joint; dislocation; Botulinum toxin type A; lateral pterygoid muscle | ||
| References | ||
|
1. Undt G, Kermer C, Piehslinger E, Rasse M. Treatment of recurrent mandibular dislocation. Part I. Leclerc blocking procedure. Int J Oral Maxillofac Surg 1997; 26: 92-7.
2. Hale RH. Treatment of recurrent dislocation of the mandible: review of literature and report of cases. J Oral Surg 1972; 30: 527-30.
3. Shorey C, Campbell J. Dislocation of the temporomandibular joint. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000; 89: 662-8.
4. Thangarajah T, McCulloch N, Thangarajah S, Stocker J. Bilateral tempromandibular joint dislocation in a 29- year-old man: a case report. J Med Case Rep 2010; 4: 263.
5. Akinbami BO. Evaluation of the mechanism and principles of management of temporomandibular joint dislocation. Systematic review of literature and a proposed new classification of temporomandibular joint dislocation. Head Face Med 2011; 7: 10.
6. Medra AM, Mahrous AM. Glenotemporal osteotomy and bone grafting in the management of chronic recurrent dislocation and hypermobility of the temporomandibular joint. Br J Oral Maxillofac Surg 2008; 46: 119-22.
7. Kummoona R. Surgical reconstruction of the temporomandibular joint for chronic subluxation and dislocation. Int J Oral Maxillofac Surg 2001; 30: 344-8.
8. Lovely FW, Copeland RA. Reduction eminoplasty for chronic recurrent luxation of the temporomandibular joint. J Can Dent Assoc 1981; 3: 179-84.
9. Daif E. Autologous blood injection as a new treatment modality for chronic recurrent temporomandibular joint dislocation. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010; 109: 31-6.
10.Leopard PJ. Surgery of the non-ankylosed temporomandibular joint. Br J Oral Maxillofac Surg 1987; 25: 138-48.
11.Sinclair CF, Gurey LE, Blitzer A. Oromandibular dystonia: long-term management with botulinum toxin. Laryngoscope 2013; 123: 3078- 83.
12.Martínez-Pérez D, García Ruiz-Espiga P. Recurrent temporomandibular joint dislocation treated with botulinum toxin: report of 3 cases. J Oral Maxillofac Surg 2004; 62: 244-6.
13.Moore AP, Wood GD. Medical treatment of recurrent temporomanibular joint dislocation using botulinum toxin A. Dent J 1997; 23: 127-32.
14.Daelen B, Thorwirth V, Koch A. Treatment of recurrent dislocation of the temporomandibular joint with type A botulinum toxin. Int J Oral Maxillofac Surg 1997; 26: 458.
15.Freund B, Schwartz M, Symington JM. Botulinum toxin: new treatment for temporomandibular disorders. Br J Oral Maxillofac Surg 2000; 38: 466-71.
16.Hambleton P, Moore AP. Botulinum neurotoxins: Origin, structure, molecular actions and antibodies. In: Moore AP (ed). Handbook of Botulinim Toxin Treatment. Oxford, England: Blackwell Scientific, 1995. 16-27.
17.Brin MF. Botulinum toxin therapy: Basic sciences and overview of other therapeutic applications. In: Blitzer A, Binder WJ, Boyd JB (eds). Management of Facial Lines and Wrinkles. Philadelphia, PA: Lippincott Williams and Wilkins, 1999. 279-302.
18.Jost WH. Botulinum Toxin in Painful Diseases. Pain Headache. Vol 14. Basel: Karger, 2003. 82-101.
19.Yang X, Pernu H, Pyhtinen J, Tiilikainen PA, Oikarinen KS, Raustia AM. MRI abnormalities of the lateral pterygoid muscle in patients with non-reducing disk displacement of the TMJ. Cranio 2002; 20: 209-21.
20.Christoph M, Ziegler CM, Haag C, Muhling J. Treatment of recurrent temporomandibular dislocation with intramuscular botulinum toxin injection. Clin Oral Invest 2003; 7: 52-5.
21. Marvin S. Treatment of the temporomandibular disorder with botulinum toxin. Clin J Pain 2002; 18: 198-203.
22. Brin MF, Fahn S, Moskowitz C, Friedman A, Shale HM, Greene PE, et al. Localized injections of botulinum toxin for the treatment of focal dystonias and hemifacial spasm. Mov Disord 1987; 2: 237.
23. Brin MF, Blitzer A, Herman S. Orofaciomandibular and lingual dystonia. In: Moore AP (eds). Handbook of Botulinim Toxin Treatment. Oxford, England: Blackwell Scientific, 1995. 151-63.
24. Bertram S, Rudisch A, Innerhofer K, Pümpel E, Grubwieser G, Emshoff R. Diagnosing TMJ internal derangement and osteoarthritis with magnetic resonance imaging. J Am Dent Assoc 2001; 132: 753-61.
25. Zuber M, Sebald M, Bathien N, de Recondo J, Rondot P. Botulinum antibodies in dystonic patients treated with type A botulinum toxin. Frequency and significance. Neurology 1993; 43: 1715-8.
26. Korean J. Oromandibular dystonia after dental treatment. Assoc Oral Maxillofac Surg 2012; 38: 379-83.
27. Colhado O, Boeing M, Borina L. Botulinum toxin in pain treatment. Rev Bras Anestesiol 2009; 59: 366-81.
28. Borodic GE, Acquadro MA. The use of botulinum toxin for treatment of chronic facial pain. J Pain 2002; 3: 21-7.
29. Von Lindern JJ. Type Abotulinum toxin in the treatment of chronic facial pain associated with temporo-mandibular dysfunction. Acta Neural Belg 2001; 101: 39-41.
30. Girdler M. Use of botulinum toxin to alleviate facial pain. Br J Hosp Med 1994; 52: 363.
31. Kandil M. The effect of botulinum toxin (botox) on persistent painful tempromandibular joint. Thesis Oral and Maxillofacial Surgery. Faculty of Dentistry. Alexandria University. Egypt. 2013. 40-3.
32. Dijkgraaf LC, de Bont LG, Boering G, Liem RS. Structure of the normal synovial membrane of the temporomandibular joint: a review of the literature. J Oral Maxillofac Surg 1996; 54: 332-8.
33. De leeuwr, Boering G, Stegena B, Bont LG. Radiographic signs of temporomandibular joint osteoarthritis and internal derangement. Oral Surg Oral Med Oral Path Oral Radiol 1995; 79: 382-93.
34. Sato S, Takahashi K, Kawamura H, Moteegi K. The natural course of non reducing disc displacement of the temporomandibular joint. Int J Oral Maxillofac Surg 1998; 27: 173-8.
35. Okeson JP. Bell's orofacial pains: The clinical management of orofacial pain. 6thed. New Malden, Surrey, UK: Quintessence Publishing Co. Ltd, 2005. 567.
36. Carruthers A, Kiene K, Carruthers J. Botulinum toxin A exotoxin use in clinical dermatology. J Am Acad Dermatol 1996; 34: 788.
37. Undt G, Weichselbraun A, Wagner A, Kermer C, Rasse M. Recurrent mandibular dislocation under neuroleptic drug therapy treated by bilateral eminectomy. J Craniomaxillofac Surg 1996; 20: 217.
| ||
|
Statistics Article View: 231 PDF Download: 1,392 |
||
